Dystrogen Therapeutics
Business Services · Illinois, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1415 W 37th St, Chicago, Illinois, 60609...Phone Number
(779) 248-2313Website
www.dystrogen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Dystrogen Therapeutics
Dystrogen Therapeutics is a clinical-stage biotech company specializing in chimeric cell therapy aimed at treating muscle wasting disorders, particularly Duchenne muscular dystrophy (DMD). The company is developing Dystrophic Expressing Chimeric (DEC) cell therapy, which offers a universal treatment option without the need for immunosuppression. Their innovative approach allows for the production of the dystrophin protein without genetic manipulation, making it suitable for all DMD patients regardless of their genetic mutations. Dystrogen Therapeutics targets patients suffering from DMD, providing a novel solution that enhances muscle function and reduces fatigue.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dystrogen Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Dystrogen Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Dystrogen Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Dystrogen Therapeutics has new funding data
Product Launch: Get notified when Dystrogen Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Dystrogen Therapeutics
Earning: See what the market has to say on Dystrogen Therapeutics recently announced quarterly report
Click to see if Dystrogen Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Dystrogen Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Dystrogen Therapeutics
Find more new buyers
Compare Similar Companies to Dystrogen Therapeutics
Compare insights from companies similar to Dystrogen Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Dystrogen Therapeutics
<$5M
1-10
Private
-
2017
N/A
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
Company Profile Activity
Activity Insights
Dystrogen Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dystrogen Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dystrogen Therapeutics.
Dystrogen Therapeutics Tech Stack
A closer look at the technologies used by Dystrogen Therapeutics
See more technologies
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Dystrogen Therapeutics
Sign Up For FreeTo access detailed company insights
Dystrogen Therapeutics is a clinical-stage biotech company specializing in chimeric cell therapy aimed at treating muscle wasting disorders, particularly Duchenne muscular dystrophy (DMD). The company is developing Dystrophic Expressing Chimeric (DEC) cell therapy, which offers a universal treatment option without the need for immunosuppression. Th... Read More
